Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 280

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 280
---
 401(k) matching contributions and certain benefits in connection                                                                                                                      
 with Mr. Prensky’s employment termination pursuant to the Prensky Separation Agreement (as defined below), which include the following: (i) eighteen (18) months of base salary ($750,000), (ii) an amount with respect to his 2024 
 annual bonus ($250,000), and (iii) eighteen (18) months of the Consolidated Omnibus Budget Reconciliation Act of 1985, or COBRA, premiums ($49,746).                                                                                |

| (7) | Commenced employment as our Chief Financial Officer in June 2024 and was subsequently terminated in May 2025. |

| (8) | Amount shown represents Company-paid 401(k) matching contributions. |

190

Narrative to the Summary Compensation Table

Annual Base Salary

Our named
executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive’s skill set,
experience, role, and responsibilities. The base salary of our named executive officers is generally determined and approved by our board of directors in connection with the commencement of employment of the named executive officer and may be
adjusted from time to time thereafter as the board of directors determines appropriate. The 2024 annual base salaries for our named executive officers were as follows: (1) $550,000 for Ms. Turner, (2) $500,000 for Mr. Prensky, (3) $410,000
for Mr. Sawhney, and (4) $375,000 for Dr. Eramo.

Bonus Compensation

In addition to base salaries, each of our named executive officers is eligible to receive a discretionary annual bonus of up to a percentage of
the executive’s gross base salary based on individual performance, Company performance or as otherwise determined appropriate, as determined by our board of directors. For the year ended December 31, 2024, cash bonus targets were 50% for
Ms. Turner, 40% for Mr. Prensky, 40% for Mr. Sawhney, and 40% for Dr. Eramo. The amount of any discretionary annual bonus is determined after the end of the year for which the bonus relates. The amounts paid to the named
executive officers for the 2024 discretionary annual bonus (other than Ms. Turner and Mr. Prensky)